BF-30 effectively inhibits ciprofloxacin-resistant bacteria in vitro and in a rat model of vaginosis

Wang, Jing; Li, Bing; Li, Yang; Dou, Jie; Hao, Qingru; Tian, Yuwei; Wang, Hui; Zhou, Changlin

추천

검색

자료유형: 학술저널

저자정보: Wang, Jing (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Li, Bing (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Li, Yang (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Dou, Jie (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Hao, Qingru (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Tian, Yuwei (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Wang, Hui (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Zhou, Changlin (State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University)

저널정보: 대한약학회 Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea 제37권 제7호

발행연도: 2014.1

수록면: 927 - 936 (10page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Bacterial infections are becoming increasingly difficult to treat due to the increasing number of multidrug-resistant strains. Cathelicidin-BF (BF-30) is a cathelicidin-like antimicrobial peptide and exhibits broad antimicrobial activity against bacteria. In the present study, the antibacterial activity of BF-30 against ciprofloxacin-resistant Escherichia coli and Staphylococcus aureus was examined, and the protective effects of this peptide against these bacteria in rats with bacterial vaginosis were identified for the first time. The data showed that BF-30 had effective antimicrobial activities against ciprofloxacin-resistant E. coli and S. aureus. The minimal inhibitory concentrations for both bacterial strains were $16{\mu}g/ml$, and the minimal bactericidal concentrations were 64 and $128{\mu}g/ml$, respectively. A time course experiment showed that the CFU counts rapidly decreased after BF-30 treatment, and the bacteria were nearly eliminated within 4 h. BF-30 could reduce the fold change (CFU/ml) in local colonization by drug-resistant E. coli and S. aureus to 0.01 at a dose of 0.8 mg/kg/day in the rats' vaginal secretions. In addition, BF-30 induced membrane permeabilization and bound to the genomic DNA, interrupting protein synthesis. Taken together, our data demonstrate that BF-30 has potential therapeutic value for the prevention and treatment of bacterial vaginosis.

#BF-30 #Antimicrobial activity #Ciprofloxacin-resistant bacteria #Vaginosis #Cytoplasmic membrane permeability #DNA binding

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요